I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313 on Oct. 3, 2007

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR 1.322 Docket No. MA-43CDF2D4 Patent No. 7,138,568

Sanders, Patent/Attorney

Applicants

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Jewel Payne, August J. Sick

Issued

November 21, 2006

Patent No.

7,138,568

For

Novel Bacillus thuringiensis Isolate Active Against Lepidopteran Pests,

and Genes Encoding Novel Lepidopteran-Active Toxins

Mail Stop Certificate of Corrections Branch Commissioner for Patents P.O. Box 1450
Alexandria, VA 22313-1450

Certificate

OCT 1 0 2007

of Correction

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR 1:322 (OFFICE MISTAKE)

Sir:

A Certificate of Correction (in duplicate) for the above-identified patent has been prepared and is attached hereto.

In the left-hand column below is the column and line number where errors occurred in the patent. In the right-hand column is the page and line number in the application where the correct information appears.

Patent Reads:

Application Reads:

Column 3, line 4:

Page 4, line [0032]:

"PS811"

--PS81I--

Column 5, line 54:

Page 7, line [0044]:

"galgene"

--gal gene--

2

Column 7, lines 58-59:

Page 10, line [0055]:

"Theological agents, surfactants"

--rheological agents, surfactants--.

A true and correct copy of pages 4, 7, and 10 of the specification as filed which support Applicants' assertion of the errors on the part of the Patent Office accompanies this Certificate of Correction.

Approval of the Certificate of Correction is respectfully requested.

Respectfully submitted,

Jay M. Sanders Patent Attorney

Registration No. 39,355

Phone No.: 352-375-8100 Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

JMS/mrc

Attachments: Copy of pages 4, 7, and 10 of the specification

Certificate of Corrections (in duplicate)

target pests. The formulation and application procedures are all well known in the art and are used with commercial strains of *B. thuringiensis* (HD-1) active against *Lepidoptera*, *e.g.*, caterpillars. *B.t.* PS81I, and mutants thereof, can be used to control lepidopteran pests.

[0032]

A subculture of *B.t.* PS81I and the *E. coli* hosts harboring the toxin genes of the invention, were deposited in the permanent collection of the Northern Research Laboratory, U.S. Department of Agriculture, Peoria, Illinois, USA. The accession numbers and deposit dates are as follows:

<u>Subculture</u>	Accession Number	Deposit Date
B.t. PS81I	NRRL B-18484	April 19, 1989
E. coli (NM522)(pMYC392)	NRRL B-18498	May 17, 1989
E. coli (NM522)(pMYC393)	NRRL B-18499	May 17, 1989
E. coli (NM522)(pMYC394)	NRRL B-18500	May 17, 1989
E. coli (NM522)(pMYC1603)	NRRL B-18517	June 30, 1989

[0033]

The subject cultures have been deposited under conditions that assure that access to the cultures will be available during the pendency of this patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 CFR 1.14 and 35 USC 122. The deposits are available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny, are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.

[0034]

Further, the subject culture deposits will be stored and made available to the public in accord with the provisions of the Budapest Treaty for the Deposit of Microorganisms, *i.e.*, they will be stored with all the care necessary to keep them viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposit, and in any case, for a period of at least 30 (thirty) years after the date of deposit or for the enforceable life of any patent which may issue disclosing the cultures. The depositor acknowledges the duty to replace the deposits should the depository be unable to furnish a sample when requested, due to the condition of the deposit(s). All restrictions on the availability to the public of the subject culture deposits will be irrevocably removed upon the granting of a patent disclosing them.

the stop codon(s), the polyadenylation signal sequence, if any, and the terminator region. This sequence as a double strand may be used by itself for transformation of a microorganism host, but will usually be included with a DNA sequence involving a marker, where the second DNA sequence may be joined to the toxin expression construct during introduction of the DNA into the host.

[0042]

By a marker is intended a structural gene which provides for selection of those hosts which have been modified or transformed. The marker will normally provide for selective advantage, for example, providing for biocide resistance, *e.g.*, resistance to antibiotics or heavy metals; complementation, so as to provide prototropy to an auxotrophic host, or the like. Preferably, complementation is employed, so that the modified host may not only be selected, but may also be competitive in the field. One or more markers may be employed in the development of the constructs, as well as for modifying the host. The organisms may be further modified by providing for a competitive advantage against other wild-type microorganisms in the field. For example, genes expressing metal chelating agents, *e.g.*, siderophores, may be introduced into the host along with the structural gene expressing the toxin. In this manner, the enhanced expression of a siderophore may provide for a competitive advantage for the toxin-producing host, so that it may effectively compete with the wild-type microorganisms and stably occupy a niche in the environment.

[0043]

Where no functional replication system is present, the construct will also include a sequence of at least 50 basepairs (bp), preferably at least about 100 bp, and usually not more than about 1000 bp of a sequence homologous with a sequence in the host. In this way, the probability of legitimate recombination is enhanced, so that the gene will be integrated into the host and stably maintained by the host. Desirably, the toxin gene will be in close proximity to the gene providing for complementation as well as the gene providing for the competitive advantage. Therefore, in the event that a toxin gene is lost, the resulting organism will be likely to also lose the complementing gene and/or the gene providing for the competitive advantage, so that it will be unable to compete in the environment with the gene retaining the intact construct.

[0044]

A large number of transcriptional regulatory regions are available from a wide variety of microorganism hosts, such as bacteria, bacteriophage, cyanobacteria, algae, fungi, and the like. Various transcriptional regulatory regions include the regions associated with the <u>trp</u> gene, <u>lac</u> gene, <u>gal</u> gene, the lambda left and right promoters, the Tac promoter, the naturally-occurring promoters associated with the toxin gene, where functional in the host. See for example, U.S. Patent Nos.

cetylpyridinium chloride; alcohols, such as isopropyl and ethanol; various histologic fixatives, such as Lugol iodine, Bouin's fixative, and Helly's fixative (See: Humason, Gretchen L., Animal Tissue Techniques, W.H. Freeman and Company, 1967); or a combination of physical (heat) and chemical agents that preserve and prolong the activity of the toxin produced in the cell when the cell is administered to the host animal. Examples of physical means are short wavelength radiation such as gamma-radiation and X-radiation, freezing, UV irradiation, lyophilization, and the like.

[0053]

The cells generally will have enhanced structural stability which will enhance resistance to environmental conditions. Where the pesticide is in a proform, the method of inactivation should be selected so as not to inhibit processing of the proform to the mature form of the pesticide by the target pest pathogen. For example, formaldehyde will crosslink proteins and could inhibit processing of the proform of a polypeptide pesticide. The method of inactivation or killing retains at least a substantial portion of the bio-availability or bioactivity of the toxin.

[0054]

The cellular host containing the *B.t.* insecticidal gene may be grown in any convenient nutrient medium, where the DNA construct provides a selective advantage, providing for a selective medium so that substantially all or all of the cells retain the *B.t.* gene. These cells may then be harvested in accordance with conventional ways. Alternatively, the cells can be treated prior to harvesting.

[0055]

The *B.t.* cells may be formulated in a variety of ways. They may be employed as wettable powders, granules or dusts, by mixing with various inert materials, such as inorganic minerals (phyllosilicates, carbonates, sulfates, phosphates, and the like) or botanical materials (powdered corncobs, rice hulls, walnut shells, and the like). The formulations may include spreader-sticker adjuvants, stabilizing agents, other pesticidal additives, or surfactants. Liquid formulations may be aqueous-based or non-aqueous and employed as foams, gels, suspensions, emulsifiable concentrates, or the like. The ingredients may include rheological agents, surfactants, emulsifiers, dispersants, or polymers.

[0056]

The pesticidal concentration will vary widely depending upon the nature of the particular formulation, particularly whether it is a concentrate or to be used directly. The pesticide will be present in at least 1% by weight and may be 100% by weight. The dry formulations will have from about 1-95% by weight of the pesticide while the liquid formulations will generally be from about 1-60% by weight of the solids in the liquid phase. The formulations will generally have from about

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO.

7,138,568

Page 1 of 1

APPLICATION NO.:

10/825,751

DATED

November 21, 2006

INVENTOR

Jewel Payne, August J. Sick

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 3,

Line 4, "PS811" should read --PS811--.

Column 5,

Line 54, "galgene" should read --gal gene--.

Column 7,

Lines 58-59, "Theological agents, surfactants" should read --rheological agents, surfactants--.

MAILING ADDRESS OF SENDER: Saliwanchik, Lloyd & Saliwanchik P.O. Box 142950 Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO.

7,138,568

Page 1 of 1

APPLICATION NO.:

10/825,751

DATED

November 21, 2006

INVENTOR

Jewel Payne, August J. Sick

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 3,

Line 4, "PS811" should read --PS81I--.

Column 5,

Line 54, "galgene" should read --gal gene--.

Column 7,

Lines 58-59, "Theological agents, surfactants" should read --rheological agents, surfactants--.

MAILING ADDRESS OF SENDER: Saliwanchik, Lloyd & Saliwanchik P.O. Box 142950 Gainesville, FL 32614-2950